Sales revitalized by meeting with investment partners and Anyfusion cylinder pump sales strategy that will contribute to the financial weakening due to the healthcare crisis

In Plan A, we had an investment meeting with S and H investment partners.

A new drug or new medical device takes 15 to 17 years to develop (①), license (②), register (③), pass the review by the KJC and the KOSDAQ (④), register (*), and become a real world reference (⑥), and become universalized (⑦), and after 20 years of patent protection (⑧), patent rights expire (⑨), and replicas appear (⑩), and the original gradually loses market dominance.  The Korean pharmaceutical, medical device, and bio industries, which do not have any original technology products that lead the global market, are limited to treating targeted diseases, but medical devices with original mechanical technology such as cylinder cartridges have endless applications.

For example, the cylinder pump of the original cylinder cartridge technology is the only cartridge technology that precisely and accurately transfers liquids, gases, and fluidized solids from fine quantities to large volumes from A to B in real time, and is the only cartridge technology that precisely and accurately transfers (injects) from A to B in real time with a machine, which until now has only been an alternative to manual operation with a syringe.  Generating high sales and net profits from various applications of the original cylinder cartridge technology is a fact of life in developed countries where the original technology is developed and commercialized, and is naturally valued highly in the stock market. Both VCs have no experience in Korea, and their refusal to recognize this is the difference in the meeting that we will show.

This is why global medical devices led by innovative technology products have a Price Earning Ratio (PER) of 30, which is more than twice as high as the pharmaceutical PER of 12. Korea is the opposite. It requires synergy between funding and technology at the right time, and today's meeting confirmed the difference, and H Investment Partners said they will consider investing when the data is ripe.  Series A, which is invested in the business model stage, Series B, which is invested to expand the market based on successful stages ①~6, and Series C or IPO for the purpose of building production facilities and factories in stage ⑦ and activating global marketing in stage ⑦, can be divided into stages, but it was a meeting to confirm the difference with H Investment Partners.

The severe financial deterioration of medical institutions is increasing day by day due to limited patient care due to the resignation of doctors and professors due to the expansion of medical schools. Major hospitals are introducing Anyfusion cylinder pump, a drug infusion pump that can contribute to financial improvement, which has been completely unrelated to profits, with partners.  The cylinder pump is equipped with ① to ⑥, and is the only safe and effective product in the world for infusion pumps, and has been designated as an innovative medical device by the FDA as STeP, and infection prevention and accuracy have determined ⑤(*). Anyfusion cylinder pump has been attracting major hospitals with the suggestion that it can contribute to their finances with the policy strategy of ⑤(*).

As a plan B, we have been walking the difficult but necessary path from ① to ⑥ with Anyfusion, which has applied for an international patent with the contributions of EZ Regular and shareholders. Thank you. Now, we will build ⑦ with strategies utilizing ⑤ and ⑥ to increase the value of investment and listing.  In Korea, we will increase the value by the breakthrough policy strategy of the Anyfusion cylinder pump based on ⑤ before the medical crisis is over, the optional marketing strategy of MRI shielding equipment, ICU rack, and central monitoring system, which are strong needs of users (medical personnel), and the activation of sales in 8 countries of the Anyfusion ACPi system, which is paid at the same time as certification in the global market.

Therefore, we will prepare for both Plan A existing VC investment, Plan B second VC investment, and Plan C technology special listing, and choose the direction to increase value according to the acceptance conditions.  The results of ① through ⑥ and the ⑤ system will be a great opportunity for us to contribute to hospitals when they need it most.

Thank you.